新聞集錦
NEW

11/19《生技股動態》
生技醫藥
NEW

2024國家藥科獎揭曉！仲恩、昱展、台新藥共9創新產品獲獎

生技醫藥
NEW

諾華斥7.45億美元攜Ratio 瞄準SSTR2放射藥物研發

生技醫藥
高齡醫學 多體學 高齡

《Nature》子刊：哈佛/史丹佛提「老化生物標記研究架構」 倡長期、多體學方法加速研究

2024-02-29/記者 巫芝岳
近(14)日，由史丹佛大學(StanfordUniversity)、哈佛醫學院(HarvardMedicalSchool)合作的研究團隊，首次提出一項標準化的「老化生物標記」研究架構(framework)，該團隊對目前的研究方法進行了歸納，提出目前基於體學(omics)的老化生物標記研究挑戰，以及應加強大規模、長時間的生物標記研究，來加速老化相關臨床研究。該論文發表於期刊《NatureMedici...
GBI International
GBIHighlights

BRIM Biotechnology, Inc. announced its three focus areas for this year's operations

2024-02-28/GlobalBio & Investment
#OphthalmologyInnovationGreatnewsfromBRIMBiotechnology,Inc.(6885.TWO)!Thecompanyhasannounceditsthreefocusareasforthisyear'soperations,whichinclude:1.ContinuingthedevelopmentofBRM421,theirleadasset...
GBI International
GBIHighlights

Sartorius experts highlighted the key specifications of the new PIC/S GMP Annex 1 regulation

2024-02-28/GlobalBio & Investment
#BiotechInsightsExcitingupdatesfromSartoriusandAdimmuneCorp(4142)'scorporateseminar!Sartoriusexperts,Tse-WeiChenandRZLin,highlightedthelatesttrendsincellculturedevelopmentandthekeyspecificationsof...
GBI International
GBIHighlights

AnHorn partnered with European startups to explore new treatment targets for prostate cancer

2024-02-28/GlobalBio & Investment
#InnovativeCollaborationAnHornMedicines,anAI-drivendrugdiscoverycompanyfocusedonproteindegradation,haspartneredwithEuropeanstartupstoexplorenewtreatmenttargetsforprostatecancer.On20February2024,Anhorn...
GBI International
GBIHighlights

PharmaEssentia and Oneness Biotech Co Ltd have been honored in Sustainability Yearbook 2024

2024-02-28/GlobalBio & Investment
#ESGExcellenceExcitingnews!PharmaEssentia(TPE:6446)andOnenessBiotechCoLtd(TPE:4743)havebeenhonoredintheprestigiousSustainabilityYearbook2024byS&PGlobalRatings.PharmaEssentiamarksahistoricmomentast...
GBI International
GBIHighlights

How does medical technology revolutionize commercial health insurance?

2024-02-28/GlobalBio & Investment
#MedicalInsuranceDidyouknowthattheaveragepersoninTaiwanhasthreeinsurancepolicies?Withtheriseofemergingmedicaltechnology,commercialhealthinsuranceisbeingrevolutionized.In2023,theBio-TaiwanCommittee(#BT...
GBI International
GBIHighlights

Leadgene Biomedical, Inc.'s LEADGENE® IS ELISA Kit has been approved by Taiwan's FDA...

2024-02-28/GlobalBio & Investment
#TFDAApprovalExcitingnews!LeadgeneBiomedical,Inc.'sLEADGENE®IndoxylSulfate(IS)ELISAKit,aCE-markedprotein-boundtoxindiagnosiskit,hasbeenapprovedbyTaiwan'sFDAasaClassIIIinvitrodiagnosticdevi...
GBI International
GBIHighlights

Nine biopharma companies have announced record-high revenues for January

2024-02-28/GlobalBio & Investment
#BiotechGrowthExcitingnewsfromthe#biopharmasector!Ninebiopharmacompanieshaveannouncedrecord-highrevenuesforJanuary,indicatingaprosperousstarttotheyear.Amongthem,AnxoPharmaceuticalTaiwanCo.Ltd(6677.TWO...
GBI International
GBIHighlights

FDA approves Onivyde® as a first-line therapy for metastatic pancreatic adenocarcinoma

2024-02-28/GlobalBio & Investment
**#FDAApproval**ExcitingnewsforPharmaEngineInc(4162.TWO)!FDAapproves#Onivyde®asafirst-linetherapyformetastaticpancreaticadenocarcinoma,markingapotentialnewstandardofcare.PharmaEngine'scollabor...
GBI International
GBIHighlights

The potential of next-generation microbiome therapy in clinical applications (8th AMC)

2024-02-28/GlobalBio & Investment
*#MicrobiomeTherapy**Canthegutmicrobiotarevolutionizecancertreatment?Insightsfromthe8thAsiaMicrobiomeConference(#AMC),heldbyIBCAcademiaSinica,NationalTaiwanUniversityHospital,and圖爾思生物科技BIOTOOLSCO.,LTD...
GBI International
GBIHighlights

Chang Gung Medical Foundation teams up with Gilead Sciences to accelerate early-stage clinical trial

2024-02-28/GlobalBio & Investment
**#ClinicalTrials**ChangGungMedicalFoundationteamsupwithGileadSciencestoaccelerateearly-stageclinicaltrials,focusingon#oncology.Thecollaborationaimstoadvanceclinicaltrialsintumorresearch,preclinicalco...
GBI International
GBIHighlights

GBI Spotlight: Dr. Han-Chung Wu

2024-02-28/GlobalBio & Investment
#GBISpotlight:Dr.Han-ChungWu(吳漢忠)MeetDr.Han-ChungWu,themanbehindthedevelopmentofprecisiontherapythroughinnovativephagedisplaytechnology.AstheDirectorofBioTrecatNBRP,AcademiaSinica,heisawell-knownfigur...

TOP
  • Global Bio and Investment Monthly
  • 讀者服務電話：+886 2 2726 1065時間：週一 ~ 週五 09:00 ~ 18:00
  • 服務信箱：[email protected]
  • 地址：110臺北市信義區信義路六段29號2樓之一, Taiwan

我們的服務